Novo Touts Future Blockbuster Launches, Disappointing Investors

Novo Nordisk plans to launch more than five blockbuster drugs by the end of the decade, signaling an aggressive pipeline strategy to defend its position in the increasingly competitive obesity-treatment market. The plan supports longer-term growth expectations but also underscores intensifying competition in a key profit pool.